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Rat Model of Lumbar Facet Joint Osteoarthritis
Associated With Facet-mediated Mechanical
Hyperalgesia Induced by Intra-articular Injection 
of Monosodium Iodoacetate
Kai Gong,† Wei Shao,† Hai Chen, Zhe Wang, Zhuo-Jing Luo*
Background/Purpose: The relationship between lumbar facet joint (LFJ) osteoarthritis (OA) and back
pain remains unclear. An OA model associated with joint pain was successfully induced by monosodium
iodoacetate (MIA) in rat knees. We aimed to establish an experimental OA model with facet-mediated 
mechanical hyperalgesia in the LFJ in rats.
Methods: We established a rat experimental model of LFJ OA with facet-mediated mechanical hyperalgesia by
injection of MIA into a single facet joint. After injection, changes in the LFJ structure were assessed histologi-
cally, and mechanical hyperalgesia in the hind paw was determined using the von Frey test. In addition,
interleukin-1β and tumor necrosis factor-α levels in the synovium were measured by enzyme-linked immunosor-
bent assay, and the inhibitory effects of celecoxib and gabapentin on mechanical hyperalgesia were evaluated.
Results: Progressive cartilage degeneration and changes in subchondral bone were observed after injection.
A biphasic pattern of mechanical hyperalgesia was noted in the hind paw. The concentrations of interleukin-
1β and tumor necrosis factor-α were significantly increased only on Days 1 and 3 when compared with
controls. Celecoxib was effective only on Day 3 and ineffective on Days 21 and 35, whereas gabapentin
kept its inhibitory effect on Days 3, 21 and 35.
Conclusion: An experimental LFJ OA model associated with facet-mediated mechanical hyperalgesia can
be established by intra-articular injection of MIA. This model might provide a useful tool for further study
to ascertain the complex mechanism of facet joint pain.
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Lumbar facet joint (LFJ) osteoarthritis (OA) is very
common among elderly patients with spondy-
lolisthesis and disc degeneration. LFJ has been
proven to be the primary pain generator in 10–15%
of patients with chronic low back pain, by diag-
nostic block and radiofrequency denervation;1
therefore, the relationship between facet joint OA
and back pain has been discussed. Correlative
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findings that support the role of OA of the facet
joints as a cause of back pain were reported by
Dolan et al,2 whereas Kailchman et al3 demon-
strated no connection between disease severity
and the level of reported LFJ pain. However, these
clinical studies have provided only a little useful
information because human studies are very re-
strictive and the source of patients or specimens is
limited. Further basic studies have been hampered
because of the lack of a useful animal model.
Monosodium iodoacetate (MIA), an inhibitor
of glyceraldehyde-3-phosphate dehydrogenase
activity, can induce degenerative changes in the
articular cartilage by direct interference with chon-
drocyte metabolism,4 and it has been success-
fully used to induce knee joint OA in rodents.5
In addition, it is interesting to find pain-related
behavior changes in MIA-induced OA models.6
As only a few studies on LFJ OA models have been
reported,7–9 we attempted to establish a new ex-
perimental model of LFJ OA in rats, associated
with facet-mediated mechanical hyperalgesia in-
duced by intra-articular injection of MIA.
Materials and Methods
All experimental procedures were approved by
the Institutional Care of Experimental Animals
Committee of the Fourth Military Medical
University, and adhered to the guidelines of the
Committee for Research and Ethical Issues of 
the International Association for the Study of
Pain.10 Three-month-old male Sprague–Dawley
rats, weighing 200–250 g, were housed under a
12-hour/12-hour light/dark cycle with free access
to food and water.
Surgical procedure and intra-articular
injection of MIA
Surgical procedures were performed under intra-
peritoneal anesthesia with 30 mg/kg sodium pen-
tobarbital (Nembutal; 50 mg/mL, Sigma, Poole,
UK). Rats were placed in a prone position and a
2-cm incision was made to the spinal midline.
The fascia was incised along the right side of the
supraspinous ligament for approximately 10 mm.
The multifidus muscle was resected and the right
L4/5 facet joint capsule was exposed under mi-
croscopy. MIA (Sigma) was dissolved in 0.9% ster-
ile saline to provide the indicated concentrations
(200 mg/mL). MIA (OA group, n = 121) or 0.9%
sterile saline (control group, n = 49) was injected
slowly into the right L4/5 facet joint at a final
volume of 5μL with a 36-gauge blunt NanoFil nee-
dle (WPI, Sarasota, FL, USA), at a rate of 2 μL/min,
controlled by an infusion pump. After injection,
the fascial layer of the muscles and the skin was
sutured.
Histological study
On post-injection Days 3, 7, 14, 21, 28, 35 and
42, histological examinations were performed in
the MIA and control groups (n = 3 on each day
from each group). Animals were killed by cervical
dislocation. The L4/5 spine was removed en bloc,
fixed in 10% neutral buffered formalin for 48
hours, decalcified, and embedded in paraffin.
Four randomly selected sections from each facet
joint were obtained for toluidine blue staining.
Degeneration of the facet joint was graded ac-
cording to a modified Mankin’s grading system11
(total possible score = 26). Two independent ex-
aminers assessed the histological findings obtained
from these specimens in a blind manner.
Behavioral test for mechanical hyperalgesia
Behavioral tests were conducted repeatedly before
injection to obtain baseline thresholds for both
groups, and then on postoperative Days 1, 3, 7, 14,
21, 28, 35 and 42 (n = 10 for each group). Ani-
mals were habituated to wire mesh bottom cages
before the tests. Mechanical hyperalgesia was eval-
uated by application of von Frey hairs (Stoelting
Instruments Inc., Wood Dale, IL, USA) in ascend-
ing order of force (0.7 g, 1.2 g, 1.5 g, 2 g, 3.6 g, 5.5 g,
8.5 g, 11.8 g, 15.1 g and 29 g) to the plantar surface
of the hind paws. Each von Frey hair was applied
to the paw for 6 seconds, and after a withdrawal
response was established, the paw was retested,
starting with the next descending von Frey hair,
until no response occurred. The lowest amount of
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force required to elicit a response was recorded
as the paw withdrawal threshold (PWT) in grams.
Measurement of concentration of
inflammatory cytokines
Synovium from the L4/5 facet joint was harvested
on post-injection Days 1, 3, 7, 14, 21 and 42
(n = 3 on each day for each group). A suspension
was made by homogenizing the tissues in ice. After
30 minutes, centrifugal separation was carried out
at 15,000 rpm at 4°C, and the supernatant was
collected and measured. We measured interleukin
(IL)-1β and tumor necrosis factor (TNF)-α by 
enzyme-linked immunosorbent assay, using the
rat IL-1β EASIA kit (Huamei Biotech Inc.,
Wuhan, China) and rat TNF-α kit (Alpco Inc.,
Salem, New Hampshire, USA). The sensitivity
was 3.12 pg/mL and 4 pg/mL, respectively. Each
assay was performed in triplicate.
Pharmacological assessment
The inhibitory effects of celecoxib (Apin Chemicals,
Abingdon, Oxon, UK; 30 mg/kg on Days 3, 21 and
42;) and gabapentin (Apin Chemicals; 100 mg/kg
on Days 3, 21 and 42) on mechanical hyperalgesia
were investigated. Baseline PWT was taken before
drug administration. Drugs or vehicle (5 mL/kg,
0.5% methyl cellulose) were administered orally
in a volume of 1 mL. The PWT was assessed at 1,
2 and 4 hours after drug treatment (n = 6 for each
drug or vehicle on each day, total number = 72).
Statistical analysis
All data are presented as means ± standard devi-
ation. For the mechanical threshold, the within
group difference was analyzed using the Friedman
test followed by the Wilcoxon signed-rank matched-
pairs test. The difference between groups at a given
time point was analyzed by the Mann–Whitney
U test. For pathology score or cytokine concen-
tration, one-way analysis of variance was used
for comparison between two groups, and least
significant difference t test was used for multiple
comparisons between time points. A p value of
< 0.05 was set as the level of statistical signifi-
cance for all tests.
Results
Degeneration of facet joint cartilage
In the control group, the cartilage did not degen-
erate at all predefined time points. The articular
surface was smooth and the matrix was densely
stained with toluidine blue (Figures 1A–D). In the
MIA group, superficial fibrillation, reduction of
toluidine blue in the superficial zone, and hyper-
trophic synovium intruding into the joint space
were observed on Day 3 (Figure 1E). By post-
injection Day 7, hypocellularity of chondrocytes
in the superficial and mid zones, vertical fissures in
the mid or deep zone, and reduction of toluidine
blue staining in the deep zone were found
(Figure 1F). By post-injection Day 21, cartilage
erosion, focal matrix loss and exposure of sub-
chondral bone were observed (Figure 1G). By
post-injection Day 42, denudation of the articu-
lar cartilage, deformation of the articular surface,
bone marrow fibrosis, and marginal osteophyte
formation were observed (Figure 1H).
The modified Mankin’s scores are summa-
rized in Figure 2. The scores differed significantly
between the control and MIA groups at each
time point (p < 0.05). In the saline control group,
the scores were constant at a low level during the
observation period. In the MIA group, the scores
increased significantly with time (p < 0.05). How-
ever, the scores were no different between Days
35 and 42 (p > 0.05).
Behavioral study
The results of the behavioral test for mechanical
hyperalgesia are shown in Figure 3. Animals in
both groups showed stable conditions before
surgery, in response to mechanical stimulation.
A significant reduction in PWT was noted in the
MIA group on Days 1, 3, 21, 28, 35 and 42 when
compared with the control group (p < 0.05). 
In the control group, no different from baseline in
PWT was found at all-time points (p > 0.05). 
In the MIA group, a biphasic pattern of change in
PWT was observed. The first phase of decrease 
in PWT reached a peak on Day 3 and was followed
by an increase on Days 7 and 14. On Days 7 and
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Figure 1. (A–D) Histological
changes of facet joints in rats after
injection of monosodium iodoac-
etate or saline on Days 3, 7, 14,
21, 28, 35 and 42 (n = 3 at each
day for each group). Normal artic-
ular cartilage was seen in saline
controls during the observation
period. (E) In the monosodium
iodoacetate group, superficial fib-
rillation, reduction of toluidine blue
in the superficial zone, and hyper-
trophic synovium intruding into
the joint space were observed on
Day 3. (F) On Day 7, hypocellularity
of chondrocytes in the superficial
and mid zones, vertical fissures
(arrows) in the mid or deep zone,
and reduction of toluidine blue
staining in the deep zone were
seen. (G) On Day 21, focal matrix
loss, cartilage erosion, and expo-
sure of subchondral bone (triangle)
were observed. (H) On Day 42,
denudation of the articular car-
tilage, deformation of the articu-
lar surface, bone marrow fibrosis
(open arrows), and marginal osteo-
phyte formation (asterisks) were
observed.
14, there was no difference in PWT value between
the control and MIA groups (p > 0.05). By post-
injection Day 21, the threshold decreased again
and reached its second trough on Day 35, and
then kept constant up to Day 42. The change in
PWT noted at the 35-day time point was not sig-
nificantly different from that noted at 42 days
post-MIA-injection (p > 0.05).
IL-1b and TNF-a level in synovium
The concentrations of IL-1β and TNF-α are shown
in Figure 4. In the control group, the concentra-
tions of IL-1β and TNF-α remained at a low level
during the observation period. Compared to the
controls, IL-1β and TNF-α levels in the MIA group
were significantly increased on Day 1 and reached
a maximum level on Day 3 (p < 0.05), whereas no
difference was observed between the two groups
on Days 7, 14, 21 and 42 (p > 0.05).
Pharmacological assessment
The effects of celecoxib and gabapentin on me-
chanical hyperalgesia at different time points are
shown in Figure 5. A significant reduction in PWT
was only found on Day 3 (p < 0.05) in the cele-
coxib group, whereas there was a lack of inhibition
on Days 21 and 35 (p > 0.05). However, adminis-
tration of gabapentin significantly reduced me-
chanical hyperalgesia on post-injection Days 3,
21 and 35 (p < 0.05).
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Figure 2. Degeneration of articular cartilage was assessed
by modified Mankin’s scores, which differed significantly
between control rats and those treated with monosodium
iodoacetate (MIA) at all-time points (*p<0.05 vs. controls).
Figure 3. Behavioral tests for mechanical hyperalgesia in
rats treated with monosodium iodoacetate (MIA) or saline
(control) were evaluated on Days 1, 3, 7, 14, 21, 28, 35
and 42 (n = 10 on each day for each group). A biphasic
pattern of change in paw withdrawal threshold was ob-
served in the MIA group. Compared to the control group, a
significant reduction in paw withdrawal threshold (PWT)
was noted in the MIA group on Days 1, 3, 21, 28, 35 and 42
(*p<0.05 vs. controls).
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Figure 4. Concentrations of (A) interleukin (IL)-1β and (B) tumor necrosis factor (TNF)-α in the synovium of rats treated
with monosodium iodoacetate (MIA) or saline (control) were measured by enzyme-linked immunosorbent assay on Days
1, 3, 7, 14, 21 and 42 (n = 3 on each day for each group). Compared to controls, IL-1β and TNF-α levels were significantly
increased on Day 1 and reached a maximum level on Day 3 (p < 0.05) in the MIA group, whereas no difference was 
observed between the two groups on Days 7, 14, 21 and 42 (p > 0.05) (*p < 0.05 vs. controls).
K. Gong, et al
150 J Formos Med Assoc | 2011 • Vol 110 • No 3
Discussion
LFJ is a true synovial joint with articular cartilage,
synovial membrane, and fibrous joint capsule.12
According to the cadaveric study of Tischer et al,13
the pathological characteristics of human LFJ OA
are progressive degeneration of articular cartilage
and subsequent changes in subchondral bone.
There have been only two studies that have re-
ported experimental models of LFJ OA. A surgi-
cal model in sheep was introduced by Moore 
et al in 1999.7 OA-like histopathological changes
in the LFJs of sheep could be induced by annular
rim incision of the discs. The surgical model has
the advantage that the cause of OA is due to the
loading change followed by disc incision and
subsequent degeneration, which is similar to 
the etiology of LFJ OA in humans.14 However, the
usefulness of surgical models is limited by the
extended time frame (18 months) required for
the classic features of OA to develop. In addition,
it is hard to mimic completely the natural progress
of LFJ OA in humans, owing to the difference in
anatomy and loading between humans and ani-
mals. Besides the surgical model, Yeh et al9 have
reported a collagenase-induced LFJ OA model.
However, measurement of facet joint pain or rela-
tive referred pain was not mentioned or included
in either of the above models. The model in our
study, which was similar to the collagenase-
induced one, was time-saving and reproducible.
Histopathological changes that closely mimicked
human OA lesions were observed within 6 weeks
after intra-articular injection of MIA. The pattern
of facet joint degeneration was time-dependent
and comprised the features of LFJ OA-like changes
at different stages. In addition, facet-mediated me-
chanical hyperalgesia was observed in our MIA-
induced model.
According to Tachihara et al,8 facet-mediated
mechanical hyperalgesia also could be found in
a rat model of LFJ inflammation. By administer-
ing a low volume of complete Freund’s adjuvant
(CFA) into a single facet joint, inflammation, car-
tilage degeneration, and concomitant pain-related
behavioral changes were induced. Tachihara et al8
have suggested that facet joint inflammation, and
not degeneration of the joint, might have been a
cause of pain. However, there are two main dif-
ferences between their CFA-induced model and
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Figure 5. Effect of celecoxib (30 mg/kg) and gabapentin (100 mg/kg) on mechanical hyperalgesia was tested on Days 3,
21 and 35 in rats treated with monosodium iodoacetate. Compared to vehicle (0.5% methyl cellulose), paw withdrawal
threshold (PWT) was only significantly reduced on Day 3 in the celecoxib-treated rats (p < 0.05), whereas gabapentin
demonstrated an inhibitory effect at all three time points (p < 0.05) (*p < 0.05 vs. controls).
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our model. First, the degree of cartilage degener-
ation in the former was mild or moderate and was
constant during the observation period, whereas
the cartilage degeneration in our MIA-induced OA
model was progressive and severe, and subsequent
changes in subchondral bone could be observed
more than 21 days after injection. Second, a reduc-
tion in mechanical threshold was noted on Days
3, 5 and 7 in the CFA-induced model, whereas a
biphasic pattern of mechanical hyperalgesia was
seen within 6 weeks in our MIA-induced model.
In the present study, changes in IL-1β and
TNF-α levels were closely associated with the first
phase of facet-mediated mechanical hyperalgesia
(1–7 days). The synovium is richly innervated by
free nerve endings15 and inflammatory cytokines
can spread to the epidural space;8 therefore, it can
be assumed that inflammation played a role in
the first phase of the facet-mediated mechanical
hyperalgesia in our MIA-induced model. The inhi-
bitory effect of celecoxib on mechanical hyperal-
gesia at Day 3 also suggested an early component
of inflammatory pain in our model. However,
the facet joint inflammation induced by MIA was
transient and largely resolved by Day 7 in our study.
Therefore, it would not be expected to mediate the
second phase of facet-mediated mechanical hyper-
algesia on Days 21, 28, 35 and 42. During the late
observation period, severe degenerative changes
in the facet joint were found, including exposure
of subchondral bone, bone marrow fibrosis, and
marginal osteophyte formation. According to Mach
et al,16 subchondral bone and bone marrow were
innervated with endings of small-diameter axons
and could potentially be a source of pain. Niva 
et al17 have indicated that exposure of subchon-
dral bone, bone marrow lesions, and osteoclast
activity might be the major causes of joint pain in
OA. Therefore, we assume that the second phase
of facet-mediated mechanical hyperalgesia in the
MIA-induced OA model might have been partly
due to these severe degenerative changes. In ad-
dition, we found that gabapentin was able to re-
verse mechanical hyperalgesia on Days 21 and 35,
whereas celecoxib lost its inhibitory effect on Days
21 and 35. This suggests that the second phase 
of facet-mediated mechanical hyperalgesia can be
regarded as neuropathic pain relative to behav-
ioral changes. However, further studies are needed
to elucidate the exact mechanism.
In summary, we describe a reproducible MIA-
induced rat model of LFJ OA that mimics the
pathological features of human OA. In addition,
obvious facet-mediated mechanical hyperalgesia
was found during the whole observation period.
Although this model could only be regarded as a
preliminary animal model of facet joint OA pain,
it might provide a useful tool for further study to
ascertain the complex mechanism involved.
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